Innovotech Inc. (TSX Venture Exchange: IOT; OTCQB: IOTCF) reported financial results for the first quarter ended March 31, 2026, revealing a significant drop in revenue and a net loss, as the company continues its strategic transformation to build a more diversified and resilient business.
Revenue for the quarter was $648,140, a decrease of 44% from the same period in the prior year. The decline was driven almost entirely by a change of activities in a large project for a major customer, which had been expected to continue through 2026. Management is actively expanding the company’s service offerings and capabilities to generate consistent recurring revenue and mitigate such client concentration risk.
Gross profit for the quarter was $202,231, with a gross margin of 31.2%, compared to 53.6% in the prior year. Margins were negatively impacted by underutilised capacity, as the Company maintained staffing and operational readiness in anticipation of executing the planned customer work. The Company recorded a net and comprehensive loss of $401,295 for the quarter, compared to net income of $63,523 in Q1 2025.
Operating expenses increased year over year, reflecting the Q1 integration of Keystone Labs and Innovotech Labs, relocating the former Keystone Labs operations to a new nearby facility, and investments in a stronger sales organization. These moves are part of Innovotech’s broader strategy to reduce reliance on any single client and build a more scalable platform.
Innovotech continued to advance its strategic transformation, including strengthening its leadership and commercial teams, and completing its OTCQB listing in the U.S. The Company operates with a strong liquidity position and maintains a meaningful equity base, providing flexibility to manage near‑term volatility while continuing to execute its longer‑term strategy.
“Management remains committed to investing in a more diversified, resilient, and scalable platform,” said Innovotech CEO Craig Milne. “The Company is continuing to execute its transformation strategy with a focus on the operational and commercial initiatives required to support long-term growth and reduce revenue concentration risk.”
The Company’s unaudited consolidated financial statements and Management’s Discussion and Analysis (“MD&A”) have been filed on SEDAR+ and the OTCIQ.
Innovotech is a life sciences services and technology company specializing in contract research, analytical, and microbial testing within regulated healthcare markets. The company is a recognized leader in biofilm science and antimicrobial testing and provides advanced laboratory services supporting medical device, pharmaceutical, and industrial product development. The company operates through ISO-certified and GMP-accredited laboratories and supports clients across multiple sectors and geographies, delivering data aligned with regulatory expectations such as those of the U.S. Food and Drug Administration and Health Canada. More information is available at https://www.innovotech.ca.
This news story relied on content distributed by NewMediaWire. Blockchain Registration, Verification & Enhancement provided by NewsRamp™. The source URL for this press release is Innovotech Reports 44% Revenue Drop in Q1 2026, Focuses on Diversification.